Odyssey Therapeutics announced its intention to go public on Nasdaq via an SEC filing on April 17, 2026, after abandoning IPO plans in June 2025.
The company previously disclosed IPO ambitions in January 2025 but withdrew due to unfavorable market conditions.1
Proceeds will primarily fund OD-001, a RIPK2 inhibitor in phase 2 trials for ulcerative colitis alone and with Takeda's Entyvio, plus advance preclinical SLC15A4 to phase 1/2a and other programs.1
Odyssey has raised $726.5 million total, with $175.7 million cash on hand as of April 2026.1
This move signals a heating biotech IPO market.1
Sources:
1. https://www.fiercebiotech.com/biotech/odyssey-charts-fresh-voyage-public-markets-after-abandoning-ipo-plans-last-year